Horizon Therapeutics Public (HZNP) Stock Forecast, Price & News

Horizon Therapeutics Public (NASDAQ:HZNP) Frequently Asked Questions

Is Horizon Therapeutics Public a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 1 sell rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Horizon Therapeutics Public stock.
View analyst ratings for Horizon Therapeutics Public or view top-rated stocks.

When is Horizon Therapeutics Public's next earnings date?

Horizon Therapeutics Public is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Horizon Therapeutics Public.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Wednesday, May, 4th. The biopharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.14 by $0.20. The biopharmaceutical company had revenue of $885.25 million for the quarter, compared to the consensus estimate of $866.39 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 32.08% and a net margin of 22.87%. The business's revenue was up 158.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.03 earnings per share.
View Horizon Therapeutics Public's earnings history.

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.90 billion-$4.00 billion, compared to the consensus revenue estimate of $3.98 billion.

What price target have analysts set for HZNP?

8 brokers have issued 1-year target prices for Horizon Therapeutics Public's shares. Their forecasts range from $121.00 to $168.00. On average, they anticipate Horizon Therapeutics Public's share price to reach $137.38 in the next year. This suggests a possible upside of 52.0% from the stock's current price.
View analysts' price targets for Horizon Therapeutics Public or view top-rated stocks among Wall Street analysts.

Who are Horizon Therapeutics Public's key executives?

Horizon Therapeutics Public's management team includes the following people:

• Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 55, Pay $5.54M) (LinkedIn Profile)
• Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 57, Pay $2.07M) (LinkedIn Profile)
• Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D., Exec. VP & Chief Medical Officer (Age 67, Pay $1.65M)
• Mr. Andy Pasternak, Exec. VP & Chief Strategy Officer (Age 51, Pay $1.67M) (LinkedIn Profile)
• Mr. Miles W. McHugh, Chief Accounting Officer & Sr. VP (Age 57) (LinkedIn Profile)
• Ms. Tina E. Ventura, Sr. VP & Chief Investor Relations Officer
• Mr. Sean M. Clayton J.D., Exec. VP & Gen. Counsel (Age 43)
• Mr. Geoffrey M. Curtis, Exec. VP of Corp. Affairs & Chief Communications Officer (Age 47) (LinkedIn Profile)
• Ms. Jane Gonnerman, Group VP of Corp. Devel., Chief of Staff & Office of the CEO
• Ms. Irina P. Konstantinovsky, Exec. VP, Chief HR Officer & Chief Diversity Officer (Age 51) (LinkedIn Profile)

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public CEO Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among Horizon Therapeutics Public's employees.

Who are some of Horizon Therapeutics Public's key competitors?

Some companies that are related to Horizon Therapeutics Public include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER).
View all of HZNP's competitors.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.84%), BlackRock Inc. (6.02%), Capital International Investors (3.08%), Paulson & CO. Inc. (2.44%), State Street Corp (2.38%) and Bank of New York Mellon Corp (1.71%). Company insiders that own Horizon Therapeutics Public stock include Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends for Horizon Therapeutics Public.

Which major investors are selling Horizon Therapeutics Public stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Woodline Partners LP, William Blair Investment Management LLC, Paulson & CO. Inc., Bank of Montreal Can, Healthcare of Ontario Pension Plan Trust Fund, Scout Investments Inc., and Renaissance Technologies LLC. Company insiders that have sold Horizon Therapeutics Public company stock in the last year include Andy Pasternak, Barry Moze, Brian K Beeler, Elizabeth HZ Thompson, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Paul W Hoelscher, and Timothy P Walbert.
View insider buying and selling activity for Horizon Therapeutics Public or view top insider-selling stocks.

Which major investors are buying Horizon Therapeutics Public stock?

HZNP stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Assenagon Asset Management S.A., BlackRock Inc., Goldman Sachs Group Inc., Sumitomo Mitsui Trust Holdings Inc., Arrowstreet Capital Limited Partnership, Deerfield Management Company L.P. Series C, and Bank of New York Mellon Corp.
View insider buying and selling activity for Horizon Therapeutics Public or or view top insider-buying stocks.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $90.35.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public has a market capitalization of $20.77 billion and generates $3.23 billion in revenue each year. The biopharmaceutical company earns $534.49 million in net income (profit) each year or $3.65 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

Horizon Therapeutics Public employs 1,890 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?

The following companies are subsidiares of Horizon Therapeutics Public: Andromeda Biotech Limited, Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, HZNP USA LLC, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Aon Limited, Horizon Pharma Dó Limited, Horizon Pharma Israel Holding Corp. Ltd, Horizon Pharma Rheumatology LLC, Horizon Pharma Trí Limited, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Schweiz GmbH, Horizon Therapeutics Services LLC, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, and River Vision Development Corp..

When was Horizon Therapeutics Public founded?

Horizon Therapeutics Public was founded in 2008.

What is Horizon Therapeutics Public's official website?

The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.

How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at [email protected], or via fax at 224-383-3001.